CHERRY HILL, N.J.--(BUSINESS WIRE)--May 24, 2006--Peter Katevatis, CEO of Mediscience (MTC) (OTCBB:MDSC - News), states "the March 31, 2006 assessment concludes that the MTC/Infotonics photonic based Biopsy Pill demonstrates great promise in providing a real-time non-invasive, preliminary means of detecting in vivo pre-cancerous and cancerous tissues in the upper digestive tract. The report compares similar competitor technology platforms upon which pill technology is being produced combining remote operation with MEMS and MOEMS technology and in vivo imaging, e.g. (GIVEN/OLYMPUS) or employing chemical analysis, e.g. (SMARTPILL), and the use of photonics data (MTC/Infotonics). The report states that the Photonic based Biopsy Pill has the potential to become a market leader in diagnostic technology, perhaps the industry standard, as a new diagnostic device that physicians will embrace as it addresses real concerns of the current marketplace. The assessment process did not reveal any obvious IP barriers to commercializing the MTC/Infotonics Photonic Biopsy Pill based on competitors' products in the market today."
